TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.
![]() TECH In 1 month Estimated | Quarterly | $0.08 Per Share |
![]() TECH 1 month ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 4 months ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 8 months ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 10 months ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 10 May 2024 Paid | Quarterly | $0.08 Per Share |
12 Aug 2025 (In 1 month) Date | | 0.5 Cons. EPS | - EPS |
6 Aug 2025 (In 3 weeks) Date | | 0.49 Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | 0.39 Cons. EPS | 0.42 EPS |
30 Oct 2024 Date | | 0.38 Cons. EPS | 0.42 EPS |
![]() TECH In 1 month Estimated | Quarterly | $0.08 Per Share |
![]() TECH 1 month ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 4 months ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 8 months ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 10 months ago Paid | Quarterly | $0.08 Per Share |
![]() TECH 10 May 2024 Paid | Quarterly | $0.08 Per Share |
12 Aug 2025 (In 1 month) Date | | 0.5 Cons. EPS | - EPS |
6 Aug 2025 (In 3 weeks) Date | | 0.49 Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | 0.39 Cons. EPS | 0.42 EPS |
30 Oct 2024 Date | | 0.38 Cons. EPS | 0.42 EPS |
Biotechnology Industry | Healthcare Sector | Kim Kelderman CEO | XDUS Exchange | US09073M1045 ISIN |
US Country | 3,100 Employees | 19 May 2025 Last Dividend | 30 Nov 2022 Last Split | 9 Feb 1989 IPO Date |
Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.
Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments: